A phase II open-label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma or transformed mycosis fungoides: The REDIRECT study design and rationale.

Cassandra Choe-Juliak,Karenza Alexis,Sylvia Schwarz,Linta Garcia,Ahmed Sawas

A phase II open-label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma or transformed mycosis fungoides: The REDIRECT study design and rationale.

2020

Cassandra Choe-Juliak
Karenza Alexis
Sylvia Schwarz
Linta Garcia
Ahmed Sawas

TPS3148Background: AFM13 is a tetravalent, bispecific (anti-CD30/anti-CD16A) recombinant antibody being developed for the treatment of CD30-positive T-cell malignancies and Hodgkin lymphoma. AFM13 ...

Keywords:

multicenter study
Oncology
Peripheral T-cell lymphoma
Internal medicine
open label
in patient
Refractory
Pathology
Medicine
CD30 positive
Mycosis fungoides

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations